Fulgent Genetics, Inc. (FLGT)

US — Healthcare Sector

Peers: MYGN PSNL DRIO CSTL CDNA BFLY ARVN VALN AVXL PACB

Automate Your Wheel Strategy on FLGT

With Tiblio's Option Bot, you can configure your own wheel strategy including FLGT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol FLGT
Rev/Share 10.2621
Book/Share 36.4486
PB 0.7789
Debt/Equity 0.0004
CurrentRatio 7.0054
ROIC -0.0495

MktCap 875433578.0
FreeCF/Share -0.6455
PFCF -44.1047
PE -20.4025
Debt/Assets 0.0004
DivYield 0
ROE -0.0382

Rating B-
Score 3
Recommendation Neutral
P/E Score 1
DCF Score 5
P/B Score 4
D/E Score 3

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Upgrade	FLGT	UBS	Neutral	Buy	--	$30	Aug. 5, 2025

News

Stock Picks From Seeking Alpha's March 2025 New Analysts

AI, ARGX, CCL, CEPU, CF, CROX, CUK, DECK, DUOL, FIGS, FLGT, GLCNF, GLNCY, HOOD, IAG, KD, MAKOF, META, MIST, MONRF, SKBL, SPTL, TMDX, TROW, UNBLF
Published: April 04, 2025 by: Seeking Alpha
Sentiment: Neutral

In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT, financials, utilities, materials, and mining—and provided ratings ranging from Strong Sell to Strong Buy. Top picks include C3.ai, Robinhood, Central Puerto, CF Industries, and Kyndryl.

image for news Stock Picks From Seeking Alpha's March 2025 New Analysts

Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy

FLGT
Published: March 20, 2025 by: Seeking Alpha
Sentiment: Positive

CFO bought 1.5 million worth on March 5th, a Price/Book ratio of 0.43x and a Net Current Assets Value (NCAV) of 0.68x that day. Now it's trading at 0.47x Price/Book Value and 0.72x NCAV, showing a significant undervaluation. However, nothing is cheap for no reason; the company is not making money and won't for a while.

image for news Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy

Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript

FLGT
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - Chairman and CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - CFO Conference Call Participants David Westenberg - Piper Sandler Lu Li - UBS Andrew Cooper - Raymond James Operator Greetings and welcome to the Fulgent Genetics Q4 2024 Conference Call and Webcast. At this time, all participants are in a listen-only mode.

image for news Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript

Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results

FLGT
Published: February 28, 2025 by: Business Wire
Sentiment: Neutral

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Results: Total Revenue of $76.2 million Core Revenue1 grew 14% year-over-year to $76.0 million GAAP loss of $5.9 million, or ($0.19) per share Non-GAAP income.

image for news Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results

1
2 (current)

About Fulgent Genetics, Inc. (FLGT)

IPO Date 2016-09-29
Website https://www.fulgentgenetics.com
Industry Medical - Diagnostics & Research
CEO Ming Hsieh
Employees 1313

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.